InvestorsHub Logo
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

Re: None

Thursday, 05/05/2011 10:47:33 AM

Thursday, May 05, 2011 10:47:33 AM

Post# of 80490
My guess is that we'll see the 113 IND filed around the time of the Amsterdam conference. What's even more exciting is that Berger confirmed the trial would use biomarkers to screen/enroll only those pts with ALK mutations. This would be like running a Ponatinib trial with only T3151 pts...and we know how great that would turn out.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.